Deutsche Bank
CTNM icon

Deutsche Bank’s Contineum Therapeutics CTNM Stock Holding History

Deutsche Bank’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$308K Sell
22,949
-3,267
-12% -$48.7K ﹤0.01% 2872
2026
Q2 		$430K Buy
+26,216
New +$344K ﹤0.01% 2854
2025
Q2 		– Sell
-16,079
Closed -$112K – 3769
2025
Q1 		$112K Hold
16,079
– – ﹤0.01% 3157
2024
Q4 		$236K Buy
+16,079
New +$255K ﹤0.01% 3025

Other funds holding CTNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Versant Venture Management
Versant Venture Management San Francisco, California $109M AUM 43.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sectoral Asset Management
Sectoral Asset Management Montreal, Quebec, Canada $157M AUM 41.41% 1-Year Est. Return
Red Tree Management
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Deutsche Bank's CTNM Position: Q3 2026 in Review

Deutsche Bank reduced its Contineum Therapeutics (CTNM) stake by 12% in Q3 2026, selling an estimated $48.7K and leaving 22,949 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

Deutsche Bank first reported a position in CTNM in Q4 2024 and has held it in 4 quarters since. The position peaked at $430K in Q2 2026. 63 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • Deutsche Bank held 22,949 shares of Contineum Therapeutics worth $308K as of Q3 2026.
  • Deutsche Bank sold 3,267 Contineum Therapeutics shares in Q3 2026, an estimated $48.7K.
  • Contineum Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #2872 holding.
  • Deutsche Bank first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Deutsche Bank's Contineum Therapeutics position peaked at $430K in Q2 2026.
  • 63 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.